ArticleBrain and behavior2025
Evaluating the Causal Effects of Serum and Cerebrospinal Fluid Metabolites on Cerebral Palsy: A Whole-Metabolome Mendelian Randomization Study.
Article in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to investigate the causal relationships between serum and cerebrospinal fluid (CSF) metabolites and cerebral palsy (CP) risk, leveraging genetic insights to identify potential biomarkers and metabolic pathways implicated in CP pathogenesis.
methodA two-sample Mendelian randomization (MR) approach was employed to analyze 1400 serum metabolites and 338 CSF metabolites. Genetic variants associated with metabolite levels were used as instrumental variables (IVs) to infer causal effects on CP risk. FINDINGS SERUM METABOLITES: Sixty-nine metabolites showed significant associations with CP risk, including 1-(1-enyl-stearoyl)-2-linoleoyl-GPE (protective effect: odd ratio [OR] = 0.84, p = 0.001) and 1,2-dipalmitoyl-GPC (risk effect: OR = 1.12, p = 0.003). CSF metabolites: 13 metabolites were significantly linked to CP, most notably 1-palmitoyl-2-palmitoleoyl-GPC (OR = 0.57, p = 0.001). Shared biomarker: Methionine sulfone exhibited protective effects in both serum and CSF. Pathway analysis: Glyoxylate/dicarboxylate metabolism and butyrate metabolism emerged as key pathways potentially influencing CP pathogenesis.
conclusionThis MR study provides novel evidence supporting the causal role of serum and CSF metabolites in CP, highlighting methionine sulfone and specific metabolic pathways as biologically significant factors. Although limitations such as sample size constraints and lack of experimental validation warrant caution, these findings underscore the therapeutic potential of targeting metabolic pathways in CP. Future research should prioritize mechanistic studies and translational exploration of identified metabolites.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.